Julia Rotow

8PUBLICATIONS

151CO-AUTHORS

Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Jul 14, 2026

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

|Jul 06, 2026

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

|May 18, 2026

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

|Apr 07, 2026

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Jan 15, 2026

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Aug 27, 2025

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci, Hui Li, Alessandro Di Federico

Pageof 2

Frequent Collaborators

Mark M Awad

Mihaela Aldea

Biagio Ricciuti

Giulio Metro

Lynette M Sholl

Narjust Florez

Alexander Drilon

Pasi A Jänne

Eleonora Gariazzo

Alessandro Di Federico

Frequent Collaborators

Mark M Awad

Mihaela Aldea

Biagio Ricciuti

Giulio Metro